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Gene–Environment Interaction in
Neurodegenerative Disease
There is provocative evidence that environmental
exposures to certain neurotoxicants (heavy met-
als, pesticides, fungicides) may play a role in the
development of neurodegenerative movement
disorders such as Parkinson disease (PD) and
amyotrophic lateral sclerosis (ALS). Recent
research on these diseases has focused on both the
underlying biological processes critical to disease
manifestation for the development of new treat-
ments and the relative roles of neurochemical and
genetic factors in their etiologies. Much work,
however, remains to be done to clarify these fun-
damental processes.
The objective of this three-year program
announcement (PA) is to stimulate research on
the relative roles of neurochemical and genetic
factors in the causation of neurodegenerative dis-
eases. This new initiative will selectively shift its
research focus each year to emphasize a different
neurodegenerative disease. In the current year,
the special focus is on soliciting research on
gene–environment interactions as a risk factor in
ALS (a fatal disease of unknown etiology marked
by the progressive degeneration of motor neu-
rons) in order to stimulate much-needed research
in this area. In succeeding years, there will be an
announcement indicating a different neurodegen-
erative disease focus area. 
Several epidemiological studies have impli-
cated gene–environment interactions in the
development of PD and ALS. Nevertheless, it is
still not clear whether differences in prevalence
rates or clusters of these diseases in various com-
munities are due to the differential distribution
of a hypothetical environmental toxicant or are
more frequent where a familial heritable defect is
more common. To date, analytic epidemiological
studies have varied in case and control selection
methodology and venues (e.g., clinics, population
bases, different countries), partly accounting for
the disparate conclusions reached by some inves-
tigators. While a good deal of research has been
devoted to the influence of the environment in
the susceptibility to PD, there has not been a
similar effort committed to ALS. 
Some progress has been made in recent years
toward understanding the biological bases of
ALS. A number of pathological, biochemical, and
electrophysiological abnormalities are found in
affected patients and are seen in postmortem ner-
vous tissues. Markers for genes in familial ALS
(FALS), both dominant and recessive, have been
identified, but they represent only a portion of
the possible gene loci. In 15–20% of FALS cases,
there is a mutation of the copper/zinc superoxide
dismutase (SOD1) gene on chromosome 21.
However, the overwhelming majority of ALS
patients do not have this mutation. Genetic stud-
ies of ALS linked to other chromosomes are
needed, especially of those genes easily influenced
by neurotoxicants.
It is significant that the first descriptions of
ALS coincided with the Industrial Revolution.
Therefore, it has been logical to consider whether
environmental contamination associated with
increased levels of industrial activity might be
implicated in its pathogenesis. The possible role
of occupational exposures in ALS has also been
investigated. Epidemiological studies have impli-
cated heavy metals and other environmental
exposures as risk factors for ALS but as yet have
not provided a clear directional lead. For exam-
ple, various studies have looked at occupational
exposure to lead, mercury, selenium, manganese,
aluminum, and iron exposure in assessing risk
factors for the disease. Calcium has also been
studied because of suggestions that excitotoxicity
and calcium channel antibodies may be implicat-
ed in its etiology. In addition, in some areas, agri-
cultural workers seem to have a higher risk of
developing ALS, whereas studies on exposure to
industrial solvents and chemicals have brought
mixed results. 
No coherent picture has emerged from
these studies, however, nor have many of them
been correlated with genetic studies. Therefore,
much remains to be learned about the mecha-
nisms through which genetic mutations and
other biological insults lead to pathology. The
genetic defects identified in FALS have lead to
the development of some useful animal models
of the disease, but more models are needed to
expand research on the abnormal biology of the
affected motor neuron and nonneuronal cells,
on nervous system response to endogenous and
environmental toxins and toxicants, and on
identification of metabolic, endocrine, and
immunological abnormalities. 
Additional research is also needed to under-
stand the contribution of environmental expo-
sure, endogenous susceptibility factors, and
increasing age in the disease linkage. This will
require a concurrent advancement and refine-
ment of methodologies and sciences. Of particu-
lar significance may be those approaches that can
be used across species from lower animals to
humans. Such approaches permit a precise char-
acterization in animal models of alterations aris-
ing from defined environmental exposures that
can serve as a cogent guide to underlying cellular
and molecular mechanisms in humans.
This initiative will seek to solicit novel
approaches to understanding ALS, with emphasis
on the role that gene–environment interactions
may play in the above. Examples of research goals
that could be pursued, especially in appropriate
animal models and tissue culture, include (but
are not limited to) the following: 
1) development of animal models of ALS,
especially nonmammalian models useful for
gene–environment research; 
2) development of biomarkers of exposure
and disease in animal models (using metabonom-
ics, for example); 
3) research on modifier genes and environ-
mental influences in animal models; 
4) studies on the intersections and synergies
between genetic susceptibilities and environmen-
tal factors, as well as strategies for identifying
putative toxicants and other environmental fac-
tors involved in the etiology of ALS; 
5) establishment of disease incidence and
variation according to age, gender, race/ethnicity,
geography, and exposure; 
6) studies on potentially informative clusters
(Western Pacific ALS/parkinsonism–dementia
complex [PDC], Persian Gulf War veterans,
Kelly Air Force Base workers, etc.); 
7) studies on occupational/environmental
exposures and nonoccupational exposures (evi-
dence for the role of metals, pesticides, solvents,
residential/avocational exposures, tobacco, alco-
hol, infectious agents); 
8) research on the potential role of dietary
excitotoxins in Western Pacific ALS/PDC and
analogies with other disorders; 
9) research on the role of dietary intake of
antioxidants and minerals (copper, zinc, iron), and
the association of fat and fiber intake with ALS; 
10) research on factors targeting putative
environmental toxicants specific to motor neu-
rons and surrounding cells including muscle cells; 
11) research on disease mechanisms on the
cellular or subcellular level (oxidative stress, excito-
toxicity, apoptosis) from neurotoxic exposures; and 
12) evaluation of retrograde axonal transport
of toxins to the spinal motor neurons and their
response (access and possible uptake of toxic sub-
stances at the neuromuscular junction).
Moreover, the NIEHS would like to encour-
age multidisciplinary and interdisciplinary stud-
ies. What may be especially useful are
collaborations with ongoing research in other
motor disorder diseases that could be expanded
to include ALS studies. We also encourage the
use of novel animal models such as Drosophila,
zebra fish and C. elegans, as well as newly avail-
able technologies. Especially useful would be col-
laborative pooling of resources to standardize
epidemiological instruments, microarray analy-
ses, “-omics” technologies, and other methods
and materials for meaningful use among several
laboratories.
This PA will primarily use the NIH Research
Project Grant (R01) and Exploratory/Develop-
mental Grant (R21) award mechanisms (though,
if appropriate, competitive supplements may be
considered if it is to accomplish collaborations).
This PA uses just-in-time concepts. It also uses
the modular as well as the nonmodular budgeting
formats (see http://grants.nih.gov/grants/
funding/modular/modular.htm). Specifically, if
you are submitting an application with direct
costs in each year of $250,000 or less, use the
modular format. Otherwise, follow the instruc-
tions for nonmodular research grant applications.
This program does not require cost sharing as
defined in the current NIH Grants Policy
Statement at http://grants.nih.gov/grants/
policy/nihgps_2001/part_i_1.htm. 
The NIEHS intends to commit approxi-
mately $2 million in fiscal year 2004 to fund
10–15 new grants in response to this PA. An
applicant may request a project period of up to
five years for R01 grants and up to two years for
R21 grants. Direct costs for R21 grants may not
exceed $275,000. The characteristics, require-
ments, preparation, and review criteria for R21
applications are described at http://grants.nih.
gov/grants/guide/pa-files/PA-03-107.html. 
Applications must be prepared using the
PHS 398 research grant application instructions
and forms (rev. 5/2001). The PHS 398 is avail-
able at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format. 
Applications submitted in response to this
PA will be accepted at the standard application
deadlines, which are available at http://grants.
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nih.gov/grants/dates.htm. Application deadlines
are also indicated in the PHS 398 application kit.
Complete information on this PA is located at
http://grants1.nih.gov/grants/guide/pa-files/
PAS-03-160.html.
Contact: Annette Kirshner, Cellular, Organs,
and Systems Pathobiology Branch, Division of
Extramural Research and Training, NIEHS, PO
Box 12233, MD-23, Research Triangle Park, NC
27709 USA, 919-541-0488, fax: 919-541-5064,
e-mail: kirshner@niehs.nih.gov. Reference: PA
No. PAS-03-160
International Bioethics Education and Career
Development Award
The Fogarty International Center (FIC), in part-
nership with the National Center for Comple-
mentary and Alternative Medicine (NCCAM),
the National Heart, Lung, and Blood Institute
(NHLBI), the National Human Genome
Research Institute (NHGRI), the National
Institute of Allergy and Infectious Diseases
(NIAID), the National Institute of Dental and
Craniofacial Research (NIDCR), the National
Institute on Drug Abuse (NIDA), the National
Institute of General Medical Sciences (NIGMS),
and the NIEHS, invites applications to develop
or expand current graduate-level curricula and
training opportunities in international bioethics
related to performing research involving human
subjects in low- and middle-income nations. As
current programs provide training for partici-
pants from the Asian, African, and Latin
American regions (for descriptions of current
programs, see http://www.fic.nih.gov/programs/
bioethics/bioethicsaward.html), new applications
focusing on countries of the Middle East; North,
East, and West Africa; Eastern Europe; and the
former Soviet Union are encouraged.
Applicant institutions can request up to four
years of support to create comprehensive curricu-
lum development and training programs.
Developing country institutions can request up
to two years of support for program planning and
curriculum development in preparation to apply
for comprehensive training program support in
the future. In addition, current International
Bioethics Education and Career Development
awardees may apply for competing supplements
to their award to collaborate with other FIC pro-
grams (for descriptions of other programs, see the
FIC web site: http://www.fic.nih.gov/programs.
html). 
Proposed curricula should provide a core set
of advanced study courses that focus primarily on
the internationally relevant aspects of the ethical,
legal, and social principles guiding the responsi-
ble conduct of research in developing countries.
Support will be provided for training developing-
country health professionals working at institu-
tions conducting biomedical, behavioral, or
public health research involving human subjects,
and for ethicists or philosophers from developing
countries with an interest in biomedical/clinical
research. Appropriate training may include
advanced degree– and nondegree-associated
course work and practicum experiences such as
participation in ethical review committees, devel-
opment of intensive short courses designed for
members of human subjects research ethical
review committees, analysis of ethical review
guidelines or processes, and research on ethical
practices in biomedical or behavioral research in
the trainees’ countries. 
This request for applications (RFA) con-
tributes to the FIC’s initiative to strengthen
research bioethics expertise in developing coun-
tries. This RFA is intended to stimulate the
development of new instructional programs in
international bioethics at institutions that do not
currently offer such programs, and to expand
existing instructional programs in international
bioethics to include a major focus on issues rele-
vant to developing countries. The goal of this ini-
tiative is to increase the cadre of biomedical and
behavioral scientists, clinical investigators, nurses,
and other health professionals and relevant acade-
mics in developing countries with state-of-the-art
knowledge of ethical considerations, concepts,
and methods in research involving human sub-
jects. It is expected that such advanced training
will enhance the career development of individu-
als from developing countries as well as strength-
en bioethical expertise at the trainees’ host
institutions.
Few developing-country institutions provide
formal training in bioethics, and few developed-
country programs for advanced bioethics training
focus in depth on the internationally relevant
aspects of bioethics, particularly those related to
clinical investigations and traditional medical
interventions in developing countries. Therefore,
few developing-country health professionals con-
ducting laboratory or clinical investigations have
received extensive training in the principles of
bioethics, codes, and legal aspects of ethical
research, ethical experimentation on vertebrate
animals, informed consent, decision making
related to collaborative agreements between hosts
and sponsors of clinical research, elements of
study design that affect the ethical conduct of
clinical trials, or interventions that should be pro-
vided to study participants.
This initiative seeks to train academics,
health professionals, and researchers from devel-
oping countries in culturally relevant bioethics
related to research. Proposed training programs
should equip them with the critical skills that are
needed to provide bioethics expertise and leader-
ship to their institutions, national governments,
and international bodies, and potentially, to pur-
sue studies on ethical practice in biomedical and
behavioral research in developing countries. The
specific objectives are as follows.
1) Curriculum development to improve the
quality of international ethics training. This
will be achieved by supporting the development
of courses in fundamental areas needed to pro-
vide skills for teaching and research related to
bioethics and the ethical review of research on
acute and chronic diseases in developing coun-
tries. Curriculum should include topics most
relevant to the bioethics issues widely experi-
enced in conducting research involving human
subjects in resource-poor settings in developing
countries. These include voluntary informed
consent, standards of medical care, sensitivity to
cultural differences, research on vulnerable pop-
ulations, benefits sharing, use of human biologi-
cal materials, human rights, conflict of interest,
equivalent protections, and harmonization of
international guidelines. Applicants are encour-
aged to develop training modules including top-
ics related to the specific research interests of the
participating NIH institutes and centers listed
above.
2) Training to support appropriate advanced
training for a cadre of developing-country profes-
sionals who could assume the expert roles and
leadership responsibilities when involved in ethics
review, clinical trials, and epidemiological studies
in their countries. Applications that provide
training for participants from the Middle East;
North, East, and West Africa; Eastern Europe;
and the former Soviet Union are particularly
encouraged.
This RFA will use the NIH R25 award
mechanism that limits facilities and administra-
tive (F&A) costs to 8% of direct costs (less
equipment). Applicants that request funding for
subcontracts to foreign organizations may also
include F&A costs up to 8% of direct costs (less
equipment). More information on the F&A
costs allowed for foreign institutions and inter-
national organizations can be found at http://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-01-028.html. The anticipated award
date is June 2004.
The participating institutes and centers
intend to commit approximately $1.8 million in
fiscal year 2004 to fund 7–8 new and/or compet-
itive continuation awards and planning/curricu-
lum development grants in response to this RFA. 
For comprehensive curriculum development
and training program awards, an applicant may
request a project period of up to four years and a
budget for total costs of up to $250,000 per year
maximum (including 8% F&A costs). 
For planning and curriculum development
grants, developing-country applicants can request
up to two years of support for a program for up
to $25,000 total costs per year (including 8%
F&A costs). 
For competing supplements, principal inves-
tigators of active International Bioethics
Education and Career Development awards may
request a supplement of up to $25,000 total costs
per year (including 8% F&A costs) for the num-
ber of years remaining in the project period of
the parent award. 
The NIDCR will provide supplements to
grantee institutions to cover the training-related
costs for oral health professionals or researchers
per year, up to a total of $200,000 per year.
The deadline for receipt of letters of intent is
17 November 2004, with 16 December 2004 the
deadline for receipt of applications. Applications
must be prepared using the PHS 398 research
grant application instructions and forms (rev.
5/2001). The PHS 398 is available at http://
grants.nih.gov/grants/funding/phs398/phs398.
html in an interactive format. Complete informa-
tion on this RFA is located at http://grants1.nih.
gov/grants/guide/rfa-files/RFA-TW-04-001.html. 
Contact: Barbara Sina, Division of Inter-
national Training and Research, FIC, 31 Center
Dr, Rm B2C39, MSC 2220, Bethesda, MD
20892-2220 USA, 301-402-9467, fax: 301-402-
0779, e-mail: sinab@mail.nih.gov. Reference:
RFA No. RFA-TW-04-001
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